Director HSE (Europe & Asia), Eli Lilly & Co.
David Revitt joined Eli Lilly & Co. in 2015 following the acquisition of Novartis Animal Health. He has primary responsibility for the global health and safety programs and coordinates health, safety and environmental (HSE) issues in Europe & Asia and across various functional networks.
David has previously held various HSE leadership roles in Novartis group in the UK, USA and Switzerland including Novartis Animal Health, Novartis Institutes for BioMedical Research, Novartis International and Novartis Horsham Research Centre.
Prior to joining the Pharmaceutical industry, David worked in academia as a senior lecturer in Microbiology and as a research veterinary microbiologist.
David is a Chartered Member of the Institution of Occupational Safety and Health (IOSH) and the International Institute of Risk and Safety Management (IIRSM) and holds various H&S qualifications, a Ph.D. in Microbiology and a B.Sc. in Applied Biology.